Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 10:43 PM ET

Biotechnology

Company Overview of PTC Therapeutics, Inc.

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical developme...

100 Corporate Court

South Plainfield, NJ 07080

United States

Founded in 1998

187 Employees

Phone:

908-222-7000

Fax:

908-222-7231

Key Executives for PTC Therapeutics, Inc.

Co-Founder, Chief Executive Officer and Executive Director
Age: 55
Total Annual Compensation: $495.0K
Chief Commercial Officer
Age: 52
Total Annual Compensation: $368.2K
Chief Medical Officer
Age: 65
Total Annual Compensation: $329.3K
Compensation as of Fiscal Year 2014.

PTC Therapeutics, Inc. Key Developments

PTC Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

PTC Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported that total revenues were $6,774,000 compared to $1,677,000 a year ago. Loss from operations was $38,626,000 compared to $25,369,000 a year ago. Net loss was $38,361,000 compared to $25,104,000 a year ago. Net loss per share applicable to common shareholders basic and diluted were $0.86 against $5.51 per share a year ago. For the six months, the company reported that total revenues were $14,256,000 compared to $10,894,000 a year ago. Loss from operations was $76,697,000 compared to $39,581,000 a year ago. Net loss was $76,276,000 compared to $39,202,000 a year ago. Net loss per share applicable to common shareholders basic and diluted were $2.29 against $1.40 per share a year ago.

PTC Therapeutics, Inc. to Report Q2, 2015 Results on Jul 30, 2015

PTC Therapeutics, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 30, 2015

PTC Therapeutics, Inc., Q2 2015 Earnings Call, Jul 30, 2015

PTC Therapeutics, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Similar Private Companies By Industry

Company Name Region
Renaissance Pharmaceuticals, Inc. United States
Vindico NanoBioTechnology, Inc. United States
Therakos, Inc. United States
Capricorn Products, LLC United States
Tempero Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC Therapeutics, Inc., please visit www.ptcbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.